Close

Northwest Biotherapeutics (NWBO) Offers Update on Phase 3 Trial Of DCVax-L for Newly Diagnosed GBM Cancer

December 8, 2016 2:06 PM EST Send to a Friend
Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login